Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.41 |
| ▸ | TTK | P33981 | 4/20 | 0.40 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765929 | 0.87 | TTK (0.49) | LRRK2TTK | |
| Ammonia Solution, Strong SCHEMBL3707460 | 0.80 | TTK (0.42) | LRRK2TTKSLCO1B1MAPT | |
| SCHEMBL4976131 | 0.74 | TTK (0.58) | LRRK2TTK | |
| SCHEMBL10270515 | 0.72 | LRRK2 (0.55) | LRRK2TTK | |
| Ammonia Solution, Strong SCHEMBL3708348 | 0.71 | TTK (0.40) | TTK | |
| Ammonia Solution, Strong SCHEMBL3704523 | 0.70 | TTK (0.51) | LRRK2TTK | |
| SCHEMBL4768728 | 0.69 | TTK (0.54) | LRRK2TTK | |
| SCHEMBL4767266 | 0.69 | TTK (0.49) | LRRK2TTK | |
| SCHEMBL4974890 | 0.69 | TTK (0.58) | LRRK2TTK | |
| SCHEMBL3704540 | 0.69 | TTK (0.49) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | MYREXIS, INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122840-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VHL, TP53, ASAH2 | LRRK2 3245/4885TTK 4589/4885SLCO1B1 1103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.